Prova Education

Early Recognition of Acute Kidney Injury: What’s the Role of Biomarkers?

Early Recognition of Acute Kidney Injury: What’s the Role of Biomarkers?

Early recognition and intervention of AKI is crucial in hospitalized patients, and certain biomarkers can help in clinical decision making.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Acute kidney injury (AKI) is a common problem faced by both nephrologists and intensivists as well as surgeons and general practitioners. AKI is increasing in hospitalized patients, and since it’s associated with both short- and long-term adverse outcomes, early recognition of patients who are at an increased risk for developing AKI is essential if we are to effectively intervene and provide optimal outcomes. Fortunately, recent data suggests that certain biomarkers can help us in clinical decision making with regard to AKI—which is the focus of this discussion.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Jay L. Koyner, MD
    Associate Professor of Medicine
    Medical Director, Acute Dialysis
    Director, ICU Nephrology
    The University of Chicago Medicine
    Chicago, IL

    No relevant relationships to report

    Sandra L. Kane-Gill, PharmD, MS, FCCM, FCCP
    Professor of Pharmacy and Therapeutics
    University of Pittsburgh School of Pharmacy
    Pittsburgh, PA

    No relevant relationships to report

    John A. Kellum, MD, MCCM
    Director of Center for Critical Care Nephrology
    Professor, Critical Care Medicine
    University of Pittsburgh
    Pittsburgh, PA

    Consutling Fees: bioMérieux
    Contracted Research: bioMérieux

    Reviewers/Content Planners/Authors:

    • Rob Braun has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the limitations of current methods of diagnosing AKI and the ramifications of a late or missed diagnosis.
    • Discuss the use of urinary biomarkers of kidney stress for early diagnosis of AKI in the critical care setting as well as tools to assess AKI risk.
    • Identify opportunities to reduce the incidence of AKI in patients at high risk of the disease.
  • Target Audience

    This activity is designed to meet the educational needs of Nephrologists, Critical Care Physicians, Surgeons, Emergency Medicine Physicians, Nurse Practitioners, Nurses, Physician Assistants and Hospital Pharmacists

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity is directly provided by GLC for physician education. For pharmacy education, it is jointly provided by Postgraduate Institute for Medicine and Prova Education.

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Prova Education.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Continuing Pharmacy Education
    Postgraduate Institute for Medicine designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number -JA4008162-9999-20-2068-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from bioMérieux.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free